BIOMARIN PHARMACEUTICAL INC Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax
BIOMARIN PHARMACEUTICAL INC (BMRN) reported Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax of -$92.54 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Income Statement › Other Income
us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax · last filed 2026-02-26
- BIOMARIN PHARMACEUTICAL INC other comprehensive income (loss), cash flow hedge, gain (loss), before reclassification, after tax for fiscal 2025 was -$92.54M, a 188.68% decline from fiscal 2024.
- BIOMARIN PHARMACEUTICAL INC other comprehensive income (loss), cash flow hedge, gain (loss), before reclassification, after tax for fiscal 2024 was $104.35M.
- BIOMARIN PHARMACEUTICAL INC other comprehensive income (loss), cash flow hedge, gain (loss), before reclassification, after tax for fiscal 2023 was -$37.72M, a 229.87% decline from fiscal 2022.
- BIOMARIN PHARMACEUTICAL INC other comprehensive income (loss), cash flow hedge, gain (loss), before reclassification, after tax for fiscal 2022 was $29.05M, a 15.52% decline from fiscal 2021.
| Period end | Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax 12 month |
|---|---|
| 2025-12-31 | -$92.54M 10-K · filed 2026-02-26 |
| 2024-12-31 | $104.35M 10-K · filed 2026-02-26 |
| 2023-12-31 | -$37.72M 10-K · filed 2026-02-26 |
| 2022-12-31 | $29.05M 10-K · filed 2025-02-24 |
| 2021-12-31 | $34.38M 10-K · filed 2024-02-26 |
| 2020-12-31 | -$23.46M 10-K · filed 2023-02-27 |
| 2019-12-31 | $25.27M 10-K · filed 2022-02-25 |
| 2018-12-31 | $25.39M 10-K · filed 2021-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |